Molecular lipid species in urinary exosomes as potential prostate cancer biomarkers

European Journal of Cancer

Volumn 70, Issue , 2017, Pages 122-132

  Skotland, Tore ^a,b   Ekroos, Kim ^c   Kauhanen, Dimple ^c   Simolin, Helena ^c   Seierstad, Therese ^a   Berge, Viktor ^a   Sandvig, Kirsten ^a,b,d   Llorente, Alicia ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c Zora Biosciences Oy   (Finland)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

Diagnostics; Exosomes; Extracellular vesicles; High throughput quantitative lipidomics; Lipids; Liquid biopsy; Non invasive biomarkers; Prostate cancer; Urine

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; ETHER LIPID; LACTOSYLCERAMIDE; LIPID; LIPIDOME; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLSERINE; SPHINGOLIPID; TUMOR MARKER;

ARTICLE; CANCER PATIENT; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; EXOSOME; HUMAN; HUMAN CELL; LIPID COMPOSITION; LIPIDOMICS; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SPHINGOLIPID METABOLISM; URINE SAMPLING; AREA UNDER THE CURVE; CASE CONTROL STUDY; CHEMISTRY; CYTOLOGY; HIGH THROUGHPUT SCREENING; PROCEDURES; PROSTATE; PROSTATIC NEOPLASMS; URINE;

AREA UNDER CURVE; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; EXOSOMES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LIPIDS; MALE; MASS SPECTROMETRY; PROSTATE; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 85000504267     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.10.011     Document Type: Article

References (52)

1. [1] Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136 (2015), E359–E386.
2. [2] Damber, J.E., Aus, G., Prostate cancer. Lancet 371 (2008), 1710–1721.
3. [3] Raposo, G., Stoorvogel, W., Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 200 (2013), 373–383.
4. [4] Colombo, M., Raposo, G., Thery, C., Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol 30 (2014), 255–289.
5. [5] Nilsson, J., Skog, J., Nordstrand, A., Baranov, V., Mincheva-Nilsson, L., Breakefield, X.O., et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br J Cancer 100 (2009), 1603–1607.
6. [6] Martins, V.R., Dias, M.S., Hainaut, P., Tumor-cell-derived microvesicles as carriers of molecular information in cancer. Curr Opin Oncol 25 (2013), 66–75.
7. [7] Thery, C., Amigorena, S., Raposo, G., Clayton, A., Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol, 2006 Chapter 3:Unit 3.22.
8. [8] Simpson, R.J., Lim, J.W., Moritz, R.L., Mathivanan, S., Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics 6 (2009), 267–283.
9. [9] Sandvig, K., Llorente, A., Proteomic analysis of microvesicles released by the human prostate cancer cell line PC-3. Mol Cell Proteomics, 11, 2012 M111.012914.
10. [10] Drake, R.R., Kislinger, T., The proteomics of prostate cancer exosomes. Expert Rev Proteomics 11 (2014), 167–177.
11. [11] Llorente, A., Skotland, T., Sylvanne, T., Kauhanen, D., Rog, T., Orlowski, A., et al. Molecular lipidomics of exosomes released by PC-3 prostate cancer cells. Biochim Biophys Acta 1831 (2013), 1302–1309.
12. [12] Corcoran, C., Rani, S., O'Driscoll, L., miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. Prostate 74 (2014), 1320–1334.
13. [13] Huang, X., Yuan, T., Liang, M., Du, M., Xia, S., Dittmar, R., et al. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol 67 (2015), 33–41.
14. [14] Hessvik, N.P., Sandvig, K., Llorente, A., Exosomal miRNAs as biomarkers for prostate cancer. Front Genet, 4, 2013, 36.
15. [15] Pisitkun, T., Shen, R.F., Knepper, M.A., Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci USA 101 (2004), 13368–13373.
16. [16] Duijvesz, D., Luider, T., Bangma, C.H., Jenster, G., Exosomes as biomarker treasure chests for prostate cancer. Eur Urol 59 (2011), 823–831.
17. [17] Mitchell, P.J., Welton, J., Staffurth, J., Court, J., Mason, M.D., Tabi, Z., et al. Can urinary exosomes act as treatment response markers in prostate cancer?. J Transl Med, 7, 2009, 4.
18. [18] Dijkstra, S., Birker, I.L., Smit, F.P., Leyten, G.H., de Reijke, T.M., van Oort, I.M., et al. Prostate cancer biomarker profiles in urinary sediments and exosomes. J Urol 191 (2014), 1132–1138.
19. [19] Fernandis, A.Z., Wenk, M.R., Lipid-based biomarkers for cancer. J Chromatogr B Anal Technol Biomed Life Sci 877 (2009), 2830–2835.
20. [20] Jung, H.R., Sylvanne, T., Koistinen, K.M., Tarasov, K., Kauhanen, D., Ekroos, K., High throughput quantitative molecular lipidomics. Biochim Biophys Acta 1811 (2011), 925–934.
21. [21] Schwudke, D., Schuhmann, K., Herzog, R., Bornstein, S.R., Shevchenko, A., Shotgun lipidomics on high resolution mass spectrometers. Cold Spring Harb Perspect Biol, 3, 2011, a004614.
22. [22] Del Boccio, P., Raimondo, F., Pieragostino, D., Morosi, L., Cozzi, G., Sacchetta, P., et al. A hyphenated microLC-Q-TOF-MS platform for exosomal lipidomics investigations: application to RCC urinary exosomes. Electrophoresis 33 (2012), 689–696.
23. [23] Hager, M.H., Solomon, K.R., Freeman, M.R., The role of cholesterol in prostate cancer. Curr Opin Clin Nutr Metab Care 9 (2006), 379–385.
24. [24] Pelton, K., Freeman, M.R., Solomon, K.R., Cholesterol and prostate cancer. Curr Opin Pharmacol 12 (2012), 751–759.
25. [25] Furuya, H., Shimizu, Y., Kawamori, T., Sphingolipids in cancer. Cancer Metastasis Rev 30 (2011), 567–576.
26. [26] Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S.I., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 (1997), 1943–1947.
27. [27] Doria, M.L., Cotrim, C.Z., Simoes, C., Macedo, B., Domingues, P., Domingues, M.R., et al. Lipidomic analysis of phospholipids from human mammary epithelial and breast cancer cell lines. J Cell Physiol 228 (2013), 457–468.
28. [28] Jeong, R.U., Lim, S., Kim, M.O., Moon, M.H., Effect of D-allose on prostate cancer cell lines: phospholipid profiling by nanoflow liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 401 (2011), 689–698.
29. [29] Zhou, X., Mao, J., Ai, J., Deng, Y., Roth, M.R., Pound, C., et al. Identification of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformatics. PLoS One, 7, 2012, e48889.
30. [30] Min, H.K., Lim, S., Chung, B.C., Moon, M.H., Shotgun lipidomics for candidate biomarkers of urinary phospholipids in prostate cancer. Anal Bioanal Chem 399 (2011), 823–830.
31. [31] Øverbye, A., Skotland, T., Koehler, C.J., Thiede, B., Seierstad, T., Berge, V., et al. Identification of prostate cancer biomarkers in urinary exosomes. Oncotarget 6 (2015), 30357–30376.
32. [32] Ekroos, K., Chernushevich, I.V., Simons, K., Shevchenko, A., Quantitative profiling of phospholipids by multiple precursor ion scanning on a hybrid quadrupole time-of-flight mass spectrometer. Anal Chem 74 (2002), 941–949.
33. [33] Bergan, J., Skotland, T., Sylvanne, T., Simolin, H., Ekroos, K., Sandvig, K., The ether lipid precursor hexadecylglycerol causes major changes in the lipidome of HEp-2 cells. PLoS One, 8, 2013, e75904.
34. [34] Ejsing, C.S., Duchoslav, E., Sampaio, J., Simons, K., Bonner, R., Thiele, C., et al. Automated identification and quantification of glycerophospholipid molecular species by multiple precursor ion scanning. Anal Chem 78 (2006), 6202–6214.
35. [35] Liebisch, G., Binder, M., Schifferer, R., Langmann, T., Schulz, B., Schmitz, G., High throughput quantification of cholesterol and cholesteryl ester by electrospray ionization tandem mass spectrometry (ESI-MS/MS). Biochim Biophys Acta 1761 (2006), 121–128.
36. [36] Stahlman, M., Ejsing, C.S., Tarasov, K., Perman, J., Boren, J., Ekroos, K., High-throughput shotgun lipidomics by quadrupole time-of-flight mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 877 (2009), 2664–2672.
37. [37] Ekroos, K., Ejsing, C.S., Bahr, U., Karas, M., Simons, K., Shevchenko, A., Charting molecular composition of phosphatidylcholines by fatty acid scanning and ion trap MS3 fragmentation. J Lipid Res 44 (2003), 2181–2192.
38. [38] Merrill, A.H. Jr., Sullards, M.C., Allegood, J.C., Kelly, S., Wang, E., Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. Methods 36 (2005), 207–224.
39. [39] Ansari, S., Baumer, K., Boué, S., Dijon, S., Dulize, R., Ekroos, K., et al. Comprehensive systems biology analysis of a 7-month cigarette smoke inhalation study in C57BL/6 mice. Sci Data, 3, 2016, 150077.
40. [40] Ogretmen, B., Hannun, Y.A., Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 4 (2004), 604–616.
41. [41] Ogretmen, B., Sphingolipids in cancer: regulation of pathogenesis and therapy. FEBS Lett 580 (2006), 5467–5476.
42. [42] Ryland, L.K., Fox, T.E., Liu, X., Loughran, T.P., Kester, M., Dysregulation of sphingolipid metabolism in cancer. Cancer Biol Ther 11 (2011), 138–149.
43. [43] Li, J., Hu, C., Zhao, X., Dai, W., Chen, S., Lu, X., et al. Large-scaled human serum sphingolipid profiling by using reversed-phase liquid chromatography coupled with dynamic multiple reaction monitoring of mass spectrometry: method development and application in hepatocellular carcinoma. J Chromatogr A 1320 (2013), 103–110.
44. [44] Kim, H., Min, H.K., Kong, G., Moon, M.H., Quantitative analysis of phosphatidylcholines and phosphatidylethanolamines in urine of patients with breast cancer by nanoflow liquid chromatography/tandem mass spectrometry. Anal Bioanal Chem 393 (2009), 1649–1656.
45. [45] Subra, C., Laulagnier, K., Perret, B., Record, M., Exosome lipidomics unravels lipid sorting at the level of multivesicular bodies. Biochimie 89 (2007), 205–212.
46. [46] Trajkovic, K., Hsu, C., Chiantia, S., Rajendran, L., Wenzel, D., Wieland, F., et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 319 (2008), 1244–1247.
47. [47] de Gassart, A., Geminard, C., Fevrier, B., Raposo, G., Vidal, M., Lipid raft-associated protein sorting in exosomes. Blood 102 (2003), 4336–4344.
48. [48] Huang, J., Buboltz, J.T., Feigenson, G.W., Maximum solubility of cholesterol in phosphatidylcholine and phosphatidylethanolamine bilayers. Biochim Biophys Acta 1417 (1999), 89–100.
49. [49] Phuyal, S., Skotland, T., Hessvik, N.P., Simolin, H., Overbye, A., Brech, A., et al. The ether lipid precursor hexadecylglycerol stimulates the release and changes the composition of exosomes derived from PC-3 cells. J Biol Chem 290 (2015), 4225–4237.
50. [50] Róg, T., Orlowski, A., Llorente, A., Skotland, T., Sylvänne, T., Kauhanen, D., et al. Interdigitation of long-chain sphingomyelin induces coupling of membrane leaflets in a cholesterol dependent manner. Biochim Biophys Acta 1858 (2015), 281–288.
51. [51] Domcke, S., Sinha, R., Levine, D.A., Sander, C., Schultz, N., Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun, 4, 2013, 2126.
52. [52] Tai, S., Sun, Y., Squires, J.M., Zhang, H., Oh, W.K., Liang, C.Z., et al. PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate 71 (2011), 1668–1679.